Abstract
We studied the influence of IL-6 on chemokine production from peripheral blood mononuclear cells (PBMC), fibroblastic synovial cells and human umbilical vessel endothelial cells (HUVEC). Moreover, we examined the effect of IL-6 on the adhesion of U937 cells to HUVEC. For chemokine production, PBMC, fibroblastic synovial cells and HUVEC were cultured with IL-6 or IL-6 + soluble IL-6R (sIL-6R) for 24 h and then the production of MCP-1 and IL-8 were measured in supernatants. IL-6 and IL-6 + sIL-6R induced production of both MCP-1 and IL-8 in PBMC and synovial cells, respectively. In HUVEC, IL-6 + sIL-6R induced MCP-1 production, but inhibited IL-8 production. For adhesion molecule expression, the production of soluble form of adhesion molecules in HUVEC culture supernatant were measured by ELISA and the expression of adhesion molecules on cell surface were examined by flow cytometry analysis. Soluble ICAM-1 was detectable in IL-6 + sIL-6R-treated HUVEC and IL-6 + sIL-6R-induced ICAM-1 expression on cell membrane of HUVEC. In addition, U937 cells were added to HUVEC, which were pre-treated with IL-6 + sIL-6R for 24 h, and 3 h later attached U937 cells were counted. The adhesion of U937 cells to HUVEC was augmented when HUVEC was pretreated by IL-6 + sIL-6R. This adhesion was suppressed by anti-ICAM-1 antibody and anti-IL-6R antibody, but not by antibodies against VCAM-1 or E-selectin. In conclusion, IL-6 signaling plays an important role in inflammatory cell migration by increasing the rate of cell adhesion and by inducing chemokine production in inflamed joints.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M et al (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5:1731–1740. doi:10.1016/j.intimp.2005.05.010
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–1769. doi:10.1002/art.20303
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997. doi:10.1016/S0140-6736(08)60453-5
Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M (2008) Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull 31:1159–1163. doi:10.1248/bpb.31.1159
Pals ST, Horst E, Scheper RJ, Meijer CJ (1989) Mechanisms of human lymphocyte migration and their role in the pathogenesis of disease. Immunol Rev 108:111–133. doi:10.1111/j.1600-065X.1989.tb00015.x
Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK et al (1992) Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 90:772–779. doi:10.1172/JCI115950
Seitz M, Dewald B, Gerber N, Baggiolini M (1991) Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest 87:463–469. doi:10.1172/JCI115018
Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P et al (1997) Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315–325. doi:10.1016/S1074-7613(00)80334-9
Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784–788. doi:10.1002/art.1780310614
Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G et al (1997) Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24:1510–1516
Aoki S, Imai K, Yachi A (1993) Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 38:485–490. doi:10.1111/j.1365-3083.1993.tb02592.x
Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J (2007) Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol 36:345–350. doi:10.1080/03009740701406460
Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM et al (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549
Hashimoto M, Shingu M, Ezaki I, Nobunaga M, Minamihara M, Kato K et al (1994) Production of soluble ICAM-1 from human endothelial cells induced by IL-1 beta and TNF-alpha. Inflammation 18:163–173. doi:10.1007/BF01534557
Pigott R, Dillon LP, Hemingway IH, Gearing AJ (1992) Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine-activated cultured endothelial cells. Biochem Biophys Res Commun 187:584–589. doi:10.1016/0006-291X(92)91234-H
Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521–1529. doi:10.1002/art.11143
Furie MB, McHugh DD (1989) Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha. J Immunol 143:3309–3317
Sung CP, Arleth AJ, Storer B, Feuerstein GZ (1991) Modulation of U937 cell adhesion to vascular endothelial cells by cyclic AMP. Life Sci 49:375–382. doi:10.1016/0024-3205(91)90445-H
Sung CP, Strorer B, Arleth A, Stadel J, Feuerstein G (1991) Evidence for the involvement of carbohydrate moieties in the adhesion of U937 cells to tumor necrosis factor-alpha (TNFalpha)-stimulated vascular endothelium in vitro. Agents Actions 34:205–207. doi:10.1007/BF01993280
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suzuki, M., Hashizume, M., Yoshida, H. et al. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30, 309–315 (2010). https://doi.org/10.1007/s00296-009-0953-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0953-0